Skip to main content

Table 1 BW

From: Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a Network Meta-Analysis of Randomized controlled trials

Standard + Glp-1

         

−0.52 (−2.54,1.49)

Glp-1

        

−1.30 (−11.03,8.44)

−0.77 (−10.33,8.79)

Standard + Flutamide

       

−1.54 (−14.74,11.67)

−1.01 (−14.10,12.07)

−0.24 (−16.25,15.77)

Roflumilast

      

−2.12 (−5.60,1.36)

−1.59 (−4.59,1.40)

−0.82 (−10.52,8.87)

−0.58 (−13.66,12.50)

Sglt-2

     

−2.30 (−10.73,6.13)

−1.77 (−10.00,6.46)

−1.00 (−10.73,8.73)

−0.76 (−16.01,14.49)

−0.18 (−8.56,8.20)

Flutamide

    

−2.69 (−6.95,1.58)

−2.16 (−6.05,1.72)

−1.39 (−11.40,8.61)

−1.15 (−14.46,12.16)

−0.57 (−4.44,3.30)

−0.39 (−9.13,8.35)

Standard + Sglt-2

   

−2.77 (−5.77,0.23)

−2.24 (−4.61,0.13)

−1.47 (−11.01,8.07)

−1.23 (−14.28,11.82)

−0.65 (−3.49,2.19)

−0.47 (−8.68,7.73)

−0.08 (−3.85,3.69)

Orlistat

  

−3.44 (−6.20,−0.67)

−2.91 (−5.04,−0.78)

−2.14 (−11.60,7.32)

−1.90 (−14.81,11.01)

−1.32 (−3.43,0.79)

−1.14 (−9.26,6.97)

−0.75 (−4.00,2.50)

−0.67 (−2.58,1.24)

Standard

 

−6.18 (−8.78,−3.57)

−5.65 (−7.44,−3.86)

−4.88 (−14.31,4.55)

−4.64 (−17.67,8.39)

−4.06 (−6.82,−1.29)

−3.88 (−11.96,4.20)

−3.49 (−7.20,0.22)

−3.41 (−5.19,−1.62)

−2.74 (−4.54,−0.94)

Placebo